Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 4/20 | 0.52 |
| ▸ | ABL1 | P00519 | 6/20 | 0.45 |
| ▸ | ULK1 | O75385 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.41 |
| ▸ | PIP5K1C | O60331 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.41 |
| ▸ | PIP5K1B | O14986 | 1/20 | 0.41 |
| ▸ | PIP5K1A | Q99755 | 1/20 | 0.41 |
| ▸ | ITK | Q08881 | 2/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.38 |
| ▸ | NPY2R | P49146 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4338506 | 0.90 | GSK3B (0.50) | ABL1MAPK14ITKGSK3B | |
| SCHEMBL4345565 | 0.87 | MAPK10 (0.47) | MAPK10ULK1MAP4K4MAPK14PIP5K1C | |
| SCHEMBL4336464 | 0.84 | ADORA3 (0.47) | ABL1MAP4K4 | |
| SCHEMBL4333966 | 0.80 | MEN1 (0.46) | ABL1GSK3B | |
| SCHEMBL4331235 | 0.80 | MEN1 (0.46) | ABL1GSK3B | |
| SCHEMBL2867285 | 0.79 | ITK (0.45) | MAP4K4MAPK8ITKGSK3B | |
| SCHEMBL4332106 | 0.79 | MAPK10 (0.47) | MAPK10ABL1MAP4K4MAPK14PIP5K1C | |
| SCHEMBL2860243 | 0.73 | TTK (0.50) | SHMT2 | |
| SCHEMBL2871320 | 0.72 | PDPK1 (0.66) | MAPK10ULK1MAPK14ITKGSK3B | |
| SCHEMBL2870995 | 0.72 | MCHR1 (0.47) | MAPK10MAPK14MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-7541376-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20050282880-A1 | Novel 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203691-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | MAPK10 29/4885ABL1 92/4885ULK1 893/4885 |
| US-20050282880-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | MAPK10 29/4885ABL1 92/4885ULK1 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.